By Brazil Stock Guide – President Luiz Inácio Lula da Silva will visit the Instituto Butantan in São Paulo on Monday (Feb. 9) to announce R$1 billion in federal investment to expand vaccine, serum and immunobiological production, according to the government. The funds will be deployed under the Novo PAC Saúde, with an additional R$400 million to come from the institute itself, which is linked to São Paulo state.
The package targets upgrades to industrial infrastructure and capacity at one of Brazil’s most strategic public health manufacturers, aligning health policy with an industrial agenda aimed at reducing dependence on imported immunobiologicals. Vice President Geraldo Alckmin, who also serves as minister of development and industry, and Health Minister Alexandre Padilha are expected to attend, highlighting the cross-ministerial scope of the initiative.
The visit coincides with the launch of nationwide dengue immunization for frontline primary care workers in the public health system. The campaign will use Butantan-DV, a dengue vaccine fully developed and produced in Brazil. The Health Ministry has contracted 3.9 million doses, with initial deliveries allocated to the first phase of the rollout across all regions.
For Brasília, the investment underscores a shift toward rebuilding domestic health manufacturing after supply shocks exposed vulnerabilities during recent global crises. By anchoring large-scale funding at Butantan, the government is betting that scale, local technology and predictable public demand can turn the institute into a pillar of Brazil’s health security — and a lever of longer-term industrial policy.
Leave a Reply